15 November 2022
LungLife AI, Inc.
("LungLife" or the "Company")
Block Listing Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:
| Name of applicant: | LungLife AI, Inc. | |||
| Name of scheme: |
| |||
| Number and class of securities originally admitted: | 1,356,139 common shares of US $0.0001 each | |||
| Date of admission: | 15 November 2021 | |||
| Period of return: | From: | 15 May 2022 | To: | 15 November 2022 |
| Balance of unallotted securities under scheme(s) from previous return: |
| |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
| |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
| |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
| |||
| Name of contact: | David Anderson, Chief Financial Officer |
| Telephone number of contact: | +44 (0)20 7933 8780 or lunglifeai@walbrookpr.com |
For the full announcement, click HERE.
"*" indicates required fields
LungLife AI licensure/accreditation information posted here.